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Abstract
In vitro disease modeling based on induced pluripotent stem cells (iPSCs) provides a pow-
erful system to study cellular pathophysiology, especially in combination with targeted ge-
nome editing and protocols to differentiate iPSCs into affected cell types. In this study, we
established zinc-finger nuclease-mediated genome editing in primary fibroblasts and iPSCs
generated from a mouse model for radiosensitive severe combined immunodeficiency (RS-
SCID), a rare disorder characterized by cellular sensitivity to radiation and the absence of
lymphocytes due to impaired DNA-dependent protein kinase (DNA-PK) activity. Our results
demonstrate that gene editing in RS-SCID fibroblasts rescued DNA-PK dependent signal-
ing to overcome radiosensitivity. Furthermore, in vitro T-cell differentiation from iPSCs was
employed to model the stage-specific T-cell maturation block induced by the disease caus-
ing mutation. Genetic correction of the RS-SCID iPSCs restored T-lymphocyte maturation,
polyclonal V(D)J recombination of the T-cell receptor followed by successful beta-selection.
In conclusion, we provide proof that iPSC-based in vitro T-cell differentiation is a valuable
paradigm for SCID disease modeling, which can be utilized to investigate disorders of T-cell
development and to validate gene therapy strategies for T-cell deficiencies. Moreover, this
study emphasizes the significance of designer nucleases as a tool for generating isogenic
disease models and their future role in producing autologous, genetically corrected trans-
plants for various clinical applications.
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Author Summary
Due to the limited availability and lifespan of some primary cells, in vitro disease modeling
with induced pluripotent stem cells (iPSCs) offers a valuable complementation to in vivo
studies. The goal of our study was to establish an in vitro disease model for severe com-
bined immunodeficiency (SCID), a group of inherited disorders of the immune system
characterized by the lack of T-lymphocytes. To this end, we generated iPSCs from fibro-
blasts of a radiosensitive SCID (RS-SCID) mouse model and established a protocol to reca-
pitulate T-lymphopoiesis from iPSCs in vitro. We used designer nucleases to edit the
underlying mutation in prkdc, the gene encoding DNA-PKcs, and demonstrated that ge-
netic correction of the disease locus rescued DNA-PK dependent signaling, restored nor-
mal radiosensitivity, and enabled T-cell maturation and polyclonal T-cell receptor
recombination. We hence provide proof that the combination of two promising technolo-
gy platforms, iPSCs and designer nucleases, with a protocol to generate T-cells in vitro,
represents a powerful paradigm for SCID disease modeling and the evaluation of thera-
peutic gene editing strategies. Furthermore, our system provides a basis for further devel-
opment of iPSC-derived cell products with the potential for various clinical applications,
including infusions of in vitro derived autologous T-cells to stabilize patients after hemato-
poietic stem cell transplantation.
Introduction
Studying the molecular pathology of human disease is often difficult due to the limited avail-
ability of particular primary cells, their limited lifespan, or because complex developmental
differentiation procedures cannot be easily followed in vivo. In vitro disease modeling with in-
duced pluripotent stem cells (iPSCs) provides a practical alternative, and the study of several
disorders has benefitted enormously from the convergence of three key technologies: modern
genomics that links genetic variants to disease phenotypes, the ability to generate patient-spe-
cific iPSCs that can be differentiated into cell types affected by disease, and powerful tools for
editing complex genomes [1,2].
T lymphocytes play an important role in adaptive immunity against invading pathogens or
in fighting tumor cells. A natural microenvironment for T-cell lymphopoiesis is provided by
the thymus. Inherited defects in T-cell function or in T-cell development can lead to severe
combined immunodeficiency (SCID), a group of life threatening disorders of the immune sys-
tem [3]. Radiosensitive SCID (RS-SCID; OMIM #602450) is characterized on the molecular
level by dysfunctional non-homologous end-joining (NHEJ), the most important pathway
to repair DNA double strand breaks (DSBs). In human patients, defective DNA repair can
lead to a cellular hypersensitivity to ionizing radiation. Moreover NHEJ is essential for physio-
logical B- and T-lymphocyte development as it plays an important role in the B-cell receptor
(BCR) and T-cell receptor (TCR) recombination process [4]. The diversity of BCRs and TCRs
results from the multitude of variable (V), divers (D) and joining (J) gene segments that are al-
most randomly reassembled in a process called V(D)J recombination. During V(D)J recombi-
nation, specific enzymes cleave at specific recombination signal sequences flanking these gene
segments and NHEJ factors play a crucial role in reassembly and final ligation of these gene
segments [5,6]. The NHEJ process involves a number of different enzymes, including DNA-de-
pendent protein kinase (DNA-PK). DNA-PK is a polyprotein complex, formed by the Ku70/
Ku80 heterodimer and the DNA-PK catalytic subunit (DNA-PKcs) [7], that binds to DNA end
structures and serves as a docking site for additional NHEJ factors that mediate DNA repair
SCID Disease Modeling
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[8]. Hypomorphic mutations in PRKDC, the locus encoding DNA-PKcs, have recently been
described for radiosensitive T and B deficient SCID patients [9]. Hence, DNA-PK dependent
signaling is a paradigmatic example of how a single molecule can be simultaneously involved
in both, DNA repair and T- and B-cell development, and of how such a process can be dis-
turbed by a single point mutation. These particularities make PRKDC an optimal target for
novel site-specific gene therapy approaches, such as designer nuclease mediated genome
editing.
For disease modeling, iPSCs can be generated from affected somatic cells by expression of
four transcription factors Oct4, Sox2, Klf4 and c-Myc [10,11]. Similar to pluripotent embryonic
stem cells, iPSCs have the capacity for unlimited self-renewal, are permissive for transfection
with foreign DNA, and importantly, can be expanded in a clonal fashion for characterization.
Thus far, iPSCs have been derived from several patients suffering from different hematopoietic
and immunological disorders and have been used for disease modeling and gene targeting ap-
proaches [12]. Several protocols for in vitro [13–21] and in vivo [22,23] differentiation of iPSCs
to hematopoietic cells have been reported. The availability of Notch ligand based cell culture
systems, such as the murine stromal cell line OP9-DL1, allows for further differentiation of he-
matopoietic stem cells into T-cells in vitro [24,25]
Targeted genome modification in iPSCs is an essential tool in disease modeling [12], and
gene editing with designer nucleases has developed into a powerful instrument, which has been
successfully applied to generate various genetically modified model organisms or human cells
to study gene function or the pathophysiology of disease causing mutations. Designer nucle-
ases, like meganucleases [26], zinc-finger nucleases (ZFNs) [27], transcription activator-like ef-
fector nucleases (TALEN) [28], or the clustered regularly interspaced short palindromic
repeats (CRISPR)/Cas9 system [29], induce site-specific DNA double strand breaks (DSBs) at
chosen sites. These DSBs activate one of two major DNA repair mechanisms, NHEJ or homol-
ogy directed repair (HDR), which can be employed to disrupt genes or to target the integration
of exogenous donor DNA sequences to a specific site in the genome, respectively [30].
The goal of this study was to establish an in vitro disease model for T-cell deficiencies and to
employ this model to evaluate a designer nuclease-based genome editing strategy. To this end,
we generated iPSCs from adult ear fibroblasts of NOD.SCID mice, a model for RS-SCID [31],
and established a protocol to recapitulate T-lymphopoiesis from iPSCs in vitro. We used ZFNs
to edit DNA-PK deficient fibroblasts and iPSCs and demonstrated that designer nuclease me-
diated gene correction led to rescue of DNA-PK dependent signaling, normal radiosensitivity,
restoration of T-cell maturation, and polyclonal TCR recombination. We hence provide proof
that the combination of two promising technology platforms, iPSCs and designer nucleases,
with a protocol to generate T-cells in vitro represents a powerful paradigm for SCID disease
modeling and the evaluation of therapeutic gene editing strategies.
Results
Restoring DNA-PK activity in SCID fibroblasts by targeted genome
editing
In the murine disease model RS-SCID is caused by a T-to-A transversion mutation in exon 85
of the prkdc locus. The introduced premature stop codon (Y4046) leads to an 83 aa long C-ter-
minal truncation of the encoded DNA-PKcs protein, leading to decreased protein stability and
low kinase activity [31]. ZFNs targeted to intron 84 of prkdc were generated using the OPEN
platform [32] and their activity verified by in vitro cleavage assays and plasmid-based recombi-
nation assays (S1 Fig). To restore function of DNA-PK, we generated a donor DNA encom-
passing the wild-type cDNA sequence of prkdc exons 85 and 86, preceded by a splice acceptor
SCID Disease Modeling
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site and followed by a poly(A) signal (Fig 1A). Targeting an intron allowed us to co-introduce a
neomycin selection marker cassette to enrich for cells that underwent correct gene targeting.
To validate our targeting strategy, fibroblasts from a 12-week old male NOD.SCID mouse,
in which the SCID mutation in prkdc was confirmed by sequencing, were isolated. Upon cul-
turing in vitro these cells transformed spontaneously, probably due to their intrinsic DNA re-
pair deficiency. The fibroblasts were transfected with various ratios of donor DNA to ZFN
expression plasmids before G418 selection was applied. An inside-out PCR strategy was used
to verify correct gene targeting in polyclonal cell populations (Fig 1B). All samples transfected
with ZFN expression plasmids and donor revealed successful gene targeting. Splicing of exon
84 to the integrated cDNA was verified by inside-out reverse transcription (RT)-PCR (Fig 1C).
Fig 1. Targeted genome editing in RS-SCID fibroblasts. (A) Schematic of genome editing strategy.
Homology-directed repair (HDR) between the prkdc locus and the donor DNA is promoted by ZFN cleavage
in intron 84 (BS, binding site). The HDR donor consists of flanking homology arms (dashed lines), splice
acceptor (SA), cDNA encoding prkdc exons 85 and 86, polyadenylation signal (pA), neomycin resistance
cassette (NeoR). The SCID underlying mutation in exon 85 (mut*), and primer binding sites for PCR analysis
(5’-junction J5-F/J5-R; 3’-junction J3-F/J3-R; allelic discrimination AD-F/AD-R; mRNA expression RT-F/
RT-R) are indicated. (B) Genome editing. After transfection of SCID fibroblasts with various ratios of donor
DNA to ZFN expression plasmids, successful gene targeting in polyclonal samples was detected by an
inside-out PCR amplification of the genome–donor 5´-junction (J5-F/J5-R). (C) Expression of corrected prkdc
mRNA. After transfection of SCID fibroblasts, successful splicing from exon 83 to cDNA was detected with an
inside-out RT-PCR strategy using primers RT-F/RT-R.
doi:10.1371/journal.pgen.1005239.g001
SCID Disease Modeling
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To determine the efficiency of the gene targeting approach, cell clones were generated by single
cell dilution. Six out of 20 analyzed clones showed correct targeting.
To confirm that re-routed splicing of exon 84 to the artificial exon 85/86 restored DNA-PK
activity, cells were treated with camptothecin (CPT), a compound known to induce DSBs dur-
ing DNA replication by blocking topoisomerase I. Under these experimental conditions, RPA2
is exclusively phosphorylated by DNA-PK at the stalled replication forks [33]. Upon CPT treat-
ment of SCID fibroblasts (Fib.S), a gene edited fibroblast clone (Fib.T) and a donor-containing
clone (Fib.D), phosphorylation of RPA2 was detected in Fib.T cells, but not in Fib.S and Fib.D
cells (Fig 2A). The fibroblast cell line NIH-3T3 served as a positive control.
Fibroblasts of RS-SCID mice are sensitive to gamma-irradiation or the radiomimetic drug
bleomycin [34]. To verify that successful gene targeting could abrogate radiosensitivity, colony
survival assays with bleomycin were conducted. We found that the corrected cell line Fib.T dis-
played similar resistance to the drug as NIH-3T3 cells, while both Fib.D and Fib.S cells were
highly sensitive to bleomycin (Fig 2B). In conclusion, successful ZFN-mediated genome editing
restored activity of DNA-PK, which was able to phosphorylate downstream target proteins and
to rescue the radiosensitive phenotype of RS-SCID cells.
Fig 2. Functional correction of RS-SCID fibroblasts. (A) DNA-PK dependent phosphorylation of RPA2.
Treatment of fibroblasts with camptothecin (CPT) induces DNA-PK dependent phosphorylation of RPA2,
which was detected byWestern blot analysis using an RPA2 specific antibody. Detection of ß-actin served as
a loading control. Positions of RPA2 and its phosphorylated form, RPA2-P, are indicated on the right. (B)
Rescue of radiosensitivity. Fibroblasts were cultured with increasing amounts of the radiomimetic drug
bleomycin. Cellular sensitivity to the drug was quantified by counting number of surviving colonies relative to
untreated samples. Data are represented as mean ± SD (N = 3). 3T3, NIH-3T3 fibroblasts; Fib.S, SCID
fibroblasts; Fib.T, gene targeted SCID fibroblasts; Fib.D, fibroblasts treated with randomly integrated donor.
doi:10.1371/journal.pgen.1005239.g002
SCID Disease Modeling
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Genetic correction of SCID iPSCs
While fibroblasts served as an important model to evaluate DNA-PK dependent signaling, the
full therapeutic potential of genome editing at the prkdc locus can only be assessed in lymphoid
cells. iPSCs have the capacity for unlimited self-renewal, allowing long-term in vitro culture
and generation of single-cell derived subclones. As iPSCs can be differentiated into hematopoi-
etic cells, including T lymphocytes, they are an ideal platform for disease modeling and the
evaluation of gene therapeutic approaches. We generated iPSCs from fibroblasts isolated from
a 6-week-old NOD.SCID mouse by transduction with a polycistronic lentiviral vector express-
ing the reprogramming factors Oct4, Klf4, Sox2 and c-Myc [35]. Since the DNA repair-defi-
cient phenotype interferes with efficient reprogramming [36], we conducted the experiment
under hypoxic conditions and added ascorbic acid to reduce damage by reactive oxygen species
(ROS) [37]. In addition, small molecule inhibitors for MAP kinase (MEK), glycogen synthase
kinase 3 (GSK3) and TGF-beta were used, which have been reported to permit derivation of
iPSCs of NOD-derived mouse strains and enhance the reprogramming progress [38,39]. All
analyzed iPSC clones expressed pluripotent stem cell markers (S2 Fig), and RT-PCR demon-
strated expression of the embryonic stem cell-specific genes in a NOD.SCID iPSC clone (iPS.
S6; Fig 3A). In addition, cells from ectodermal (neural rosette-like structures), endodermal
(gut-like structures) and mesodermal (smooth muscle patches) origin were detected in terato-
ma derived from clone iPS.S6 (Fig 3B). Genome integrity was assessed before and after ZFN
mediated genome engineering by spectral karyotyping (Figs 3C and S2). The NOD.SCID iPSC
clone iPS.S6 displayed no gross genetic abnormalities and was used for subsequent gene target-
ing experiments. In summary, we showed that DNA-repair deficient NOD.SCID fibroblasts
could be reprogrammed into iPSCs that display pluripotent behavior and characteristics simi-
lar to murine embryonic stem cells.
For targeted genome editing, cells of iPSC clone iPS.S6 were nucleofected with donor and
ZFN expression plasmids. Following selection and clonal expansion, inside-out PCR amplifica-
tion was applied on genomic DNA to detect correct targeting. Of note, 41 out of 46 analyzed
clones (89%) showed correct integration of the artificial exon 85/86. Extended PCR analysis of
five targeted iPSC clones verified correct 5´- and 3´-junctions between genomic and donor
DNA, respectively. An allelic discrimination PCR confirmed mono-allelic targeting in all cases
(Fig 4A). Furthermore, expression of the DNA-PKcs encoding mRNA and re-routed splicing
to artificial exon 85/86 was validated by inside-out RT-PCR (Fig 4B). All targeted iPSC clones
were positive for expression of pluripotency markers (Fig 3A), formed all three germ layers in
teratoma assays (Figs 3B and S2), had an intact karyotype (Figs 3C and S2), and did not show
any signs of NHEJ-mediated mutagenesis at the top 15 predicted off-target sites in the mouse
genome (S1 Table, S1 Text).
The polycistronic lentiviral vector used for generation of iPSCs contained Flp recognition
target (FRT) sites in the U3 region of the long-terminal repeats, which allowed us to excise the
reprogramming cassette using retroviral-mediated transfer of Flp recombinase [40]. Southern
blot analysis confirmed successful removal of the lentiviral vector genome (S3 Fig) and targeted
integration of the artificial exon 85/86 into intron 84 of the prkdc locus (S3 Fig).
Differentiation of iPSCs to TCR-positive T lymphocytes
Since DNA-PK is essential for V(D)J recombination, the RS-SCID immunophenotype is char-
acterized by a lack of T and B-lymphocytes [41]. The stromal cell line OP9-DL1 leads to activa-
tion of the DL1-mediated Notch signaling in co-cultured cells, which in turn is a prerequisite
to induce the T-lymphoid program in multipotent hematopoietic progenitors [24]. Initial ex-
periments showed that OP9-DL1 co-cultivation of C57BL/6-derived lineage negative bone
SCID Disease Modeling
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marrow cells enabled the differentiation of these multipotent stem cells through all (CD4-/
CD8-) double-negative (DN) thymocyte stages, as determined by CD25 and CD44 surface ex-
pression. Further culturing of these T-cell precursors on OP9-DL1 led to the generation of
CD4+/CD8+ double-positive (DP) T lymphocytes, which expressed the beta chain of the T-cell
receptor (TCRß), indicating that these cells have successfully undergone V(D)J recombination
and beta-selection in vitro (Fig 5).
Since V(D)J recombination is initiated at the DN2 (CD44+/CD25+) stage and beta-selection
occurs at the DN3 (CD44-/CD25+) stage, we hypothesized that corrected RS-SCID iPSC-de-
rived hematopoietic progenitor cells (HPCs) should be able to differentiate to CD4+/CD8+
double-positive T lymphocytes, while T-cells derived from uncorrected SCID-derived iPSCs
would stop at the DN2 thymocyte stage due to their defect in V(D)J recombination (Fig 5A).
Fig 3. Evaluation of pluripotency of generated iPSCs. (A) Pluripotent stem cell marker gene expression.
Oct3/4, Nanog, Zfp42, Esg1, Eras, and fgf4 mRNA expression was determined by qualitative RT-PCR (see
S2 Table). Housekeeping gene 36B4 (+/- reverse transcriptase) were included as controls. ES.CCE, murine
embryonic stem cell line; Fib.S, SCID fibroblasts; iPS.S6, SCID iPSC clone; iPS.T8, iPS.T25, iPS.T44, gene
targeted SCID iPSC clones; iPS.WT, wild-type iPSC clone. (B) In vivo differentiation analysis. Teratoma
formation was induced by subcutaneous injection of iPSCs into mice. Hematoxylin/eosin-stained sections
of teratoma-derived from clones iPS.S6 and iPS.T25 are shown. (C) Karyotype analysis. Spectral
karyotyping (SKY) was performed to detect microscopic genomic abnormalities, translocations and
aneuploidies in untreated or genetically corrected SCID iPSC clones. SKY analysis of clone iPSC.T25 is
shown (see also S2 Fig).
doi:10.1371/journal.pgen.1005239.g003
Fig 4. Targeted genome editing in SCID-derived iPSCs. (A) Verification of gene targeting. Inside-out PCR
strategies (see Fig 1A) were used to verify correct 5´ (J5) and 3´-junctions (J3) of the integrated donor. Allelic
discrimination (AD) PCR was used to assess mono- vs. bi-allelic integration. Targeted allele runs at 2.99 kb.
Sizes of all expected PCR amplicons are indicated on the right. iPS.WT, wild-type iPSC; iPS.S6, SCID iPSC
clone; iPS.T8, iPS.T25, iPS.T44, iPS.T45 and iPS.T60, targeted SCID iPSC clones. (B) Expression of
corrected prkdcmRNA. Successful splicing from exon 83 to cDNA encompassing exons 84/85 was detected
by an inside-out RT-PCR strategy using primers RT-F/RT-R.
doi:10.1371/journal.pgen.1005239.g004
SCID Disease Modeling
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To this end, we established an embryoid body (EB)-based differentiation protocol for the gen-
eration of HPCs from iPSCs. Differentiated and dissociated EBs from all iPSC clones contained
cells carrying the early hematopoietic surface markers CD41 and cKit (S4 Fig). Co-cultivation
of these cells on OP9-DL1 stroma cells induced differentiation towards T-lymphocytes. After
two weeks, thymocyte maturation of iPSC-derived HPCs was measured by flow cytometry, re-
vealing the presence of CD44+/CD25- (DN1), CD44+/CD25+ (DN2), CD44-/CD25+ (DN3),
CD44-/CD25- (DN4), and CD4+/CD8+ (DP) cells from wild-type iPSCs (iPS.WTX; Fig 5). As
hypothesized, T-cell differentiation of NOD.SCID iPSCs (iPS.S6X) was blocked in early DN1
and DN2 thymocyte stages and these T-cell precursors showed neither expression of CD4/
CD8 nor TCRß. In contrast, differentiation from genetically corrected iPSC clones (iPS.T25X)
reached DN3 and DN4 stages as well as the CD4+/CD8+ DP T-cell stage, with a fraction of cells
expressing TCRß (Fig 5B). Although the same experimental conditions were applied, the abso-
lute numbers of generated T-cells varied in between different experiments.
To confirm T-cell receptor recombination on the genome level, V(D)J recombination was
verified by spectratyping. Control T-cells isolated from the thymus and in vitro generated T-
cells from bone marrow lineage negative cells showed a polyclonal T-cell repertoire at Vß
chains 1, 6, 8.1, 8.3, 10, 12, 14 and 20 (Figs 6 and S5). While V(D)J recombination was unde-
tectable in T-cell precursors derived from SCID iPSCs, T lymphocytes derived fromWT or
gene targeted iPSCs underwent V(D)J recombination and revealed a polyclonal T- cell
repertoire.
In summary, we developed a protocol, which allowed us to model T-cell differentiation in
vitro. We showed that iPSCs can be differentiated into hematopoietic progenitors and further
to various stages of thymocyte development. While wild-type and corrected NOD.SCID iPSCs
could be maturated into CD45+ CD4+/CD8+ DP T-cells that express TCRß, differentiation of
DNA-PK-deficient cells stopped at the DN2 thymocyte stage. These results provide a proof of
concept that iPSC-based in vitro disease modeling is able to reflect in vivo thymocyte matura-
tion and that such modeling can be used for both to investigate T-cell maturation defects and
to validate gene therapy strategies.
Discussion
SCID is a group of monogenetic disorders of the immune system characterized by the absence
of T-cells, sometimes in combination with a lack of functional B-lymphocytes and/or natural
killer cells. RS-SCID is a special form of SCID disorders and serves as a paradigm for radiosen-
sitivity and immunodeficiency. On top of the absence of T- and B-lymphocytes, the pathophys-
iology of RS-SCID is characterized by a strong sensitivity of all somatic cells to radiation and
DNA damaging agents due to a defective DNA repair pathway. The underlying mutations are
found in genes coding for NHEJ factors, including LIG4 [42], Artemis [43], XLF [44] and
DNA-PKcs [9].
Disease modeling based on patient-derived iPSCs is particularly valuable when studying
rare disorders, like RS-SCID, for which patient cells are not easily accessible, have a limited
Fig 5. In vitro differentiation of iPSCs to proT-cells and T-cells. (A) Schematic of in vitro T-cell differentiation from iPSCs. Differentiation of iPSCs starts
with formation of embryoid bodies that are dissociated to give rise to hematopoietic stem and progenitor cells (HPC). DL-1 mediated Notch signaling coaxes
HPC development towards early proT-cells (DN2), which undergo DNA-PK dependent V(D)J recombination. After passing through DN3 and DN4 stages,
preT-cells mature into double-positive (DP) T-cells that express the beta chain of the T-cell receptor (TCRß). Dashed lines indicate to what stage iPSC clones
are expected to differentiate. (B) Assessment of T-cell differentiation. In vitro T-cell differentiation was analyzed by flow cytometry after two weeks of co-
cultivation on OP9-DL1. Gating (indicated on top of each column) was applied in the following order: FSC/SSC and CD45+/DAPI—to assess CD4/CD8
expression; CD8–/CD4—to gate for DN1-DN4 stage cells; CD8–/CD4– (DN) or CD8+/CD4+ (DP) to assess TCRß expression. Numbers indicate percentage of
cells in each quadrant. HPC, lineage-negative bone marrow cells; iPS.WTX, wild-type iPSC; iPS.S6X, SCID iPSC clone; iPS.T25, gene targeted SCID
iPSC clone.
doi:10.1371/journal.pgen.1005239.g005
SCID Disease Modeling
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lifespan, or do not develop due to a differentiation block. Designer nuclease-based gene editing
in iPSCs makes this instrument even more attractive because it enables scientists to correlate
genotype to phenotype in an isogenic background, either by creating disease models through
the insertion of disease specific mutations in normal cells [45] or by correcting the underlying
genetic mutation back to wild-type in patient-derived iPSCs [16,46]. Particularly in combina-
tion with genetic engineering, iPSCs are preferred over fibroblasts because of their unlimited
proliferative potential and their ability of clonal expansion.
Hematopoietic differentiation protocols offer the possibility to investigate maturation of
various blood lineages in vitro, e. g. to study the impact of genomic mutations on protein func-
tion in mature blood cells or where specific mutations lead to a block in lymphopoiesis, myelo-
poiesis, or erythropoiesis [17,18,46]. While designer nuclease-based gene editing in iPSCs has
been established in several labs, differentiation of genetically modified iPSCs to mature im-
mune cells has remained challenging. Differentiation of iPSCs derived from a patient suffering
from X-linked chronic granulomatous disease (X-CGD) to granulocytes was the first example
to show functional correction of a genetic defect by targeted integration of a gp91phox expres-
sion cassette into the putative safe harbor site AAVS1 [15]. Myeloid differentiation from pa-
tient-derived iPSCs for disease modeling and/or drug development has also been established
e.g. for severe congenital neutropenia [47] and pulmonary alveolar proteinosis [20].
Differentiation of iPSCs to lymphocytes, on the other hand, has been reported only from a
few labs [18,19]. In the present study, we describe an improved in vitro differentiation proce-
dure for iPSCs to T-cells that is based on previously published protocols [18,48,49], and, to our
knowledge, use this protocol for the first time to model the functional defects of an immunode-
ficiency in vitro and to investigate the effect of genetic engineering of disease iPSCs on T-cell
maturation. Because the generated hematopoietic progenitor cells supported the maturation
through all early stages of thymocyte differentiation, including V(D)J recombination and beta-
selection, we were able to reproduce the stage-specific block induced by the point mutation in
the prkdc locus in vitro. This setup can also be used to screen for genotype-phenotype
Fig 6. Polyclonal T-cell receptor recombination. In vitro generated T-cells were analyzed by spectratyping, i.e. quantitative RT-PCR expression analysis
of the variable beta chains. Exemplarily shown are results for Vß1, Vß8.3 and Vß10 (see also S5 Fig). X-axis depicts detected PCR fragment size in bp, Y-
axis depicts counts of obtained PCR fragments. Thymus, T-cells isolated from thymus as a positive control; HSC, in vitro generated T-cells from lineage-
negative bone marrow cells; iPS.WTX, wild-type iPSCs; iPS.S6X, SCID iPSC clone; iPS.T25X, gene targeted SCID iPSC clone.
doi:10.1371/journal.pgen.1005239.g006
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correlations or to characterize the consequence of newly identified genetic mutations on T-
lymphopoiesis and/or T-lymphocyte function in more detail. For instance, as compared to in
vivomodels, individual effects of the microenvironment, cytokines and/or small molecules af-
fecting T-cell maturation and expansion, like IL-7 or IL-2, can be analyzed by simple addition
to the culture medium. Moreover, existing stroma-free models can be further developed [50] to
identify factors downstream of Delta-like Notch ligands that promote T-cell development. Fi-
nally, the efficiency of T-cell related gene therapy approaches can be assessed in vitro, without
the need of hematopoietic stem cells of the patients.
In our study we applied ZFNs for genetic modification of RS-SCID iPSCs. The generation of
highly specific ZFNs can be rather challenging and several studies have described off-target
cleavage activity of ZFNs [51,52]. While the specificity of ZFNs can be improved, e.g. by opti-
mizing the DNA binding properties of the zinc-finger arrays [32], selecting appropriate linker
domains [53,54] and employing obligate heterodimeric FokI nuclease domains [55,56], alterna-
tive designer nucleases, such as TALENs [28] and CRISPR/Cas9 based nucleases [29], are easier
to engineer.
Our system provides a basis for further development of iPSC-derived cell products with the
potential for various clinical applications. However, although we have tried to transplant iPSC-
derived hematopoietic stem/precursor cells into NOD.SCID mice, we did not observe any en-
graftment of these cells. This is in line with published data showing that transplantation
worked only with iPSC-derived hematopoietic stem/precursor cells that were produced in vivo
[22,23]. Further studies will be needed to establish optimal culture conditions to generate trans-
plantable stem cells in vitro. Hence, combining in vitro protocols with physiologic in vivo dif-
ferentiation seems more promising. For example, transplantation of iPSC-derived early
thymocyte progenitor populations could allow for thymic reconstitution and maturation to
create polyclonal T-cell effector populations [50]. Infusions of in vitro derived autologous T-
cells could be used to stabilize patients suffering from primary immunodeficiencies, like SCID
or hemophagocytic lymphohistiocytosis, or after conventional hematopoietic stem cell trans-
plantation to close the gap until graft-derived lymphocytes arise. Moreover, given the clinical
success of autologous T-cells expressing tumor specific chimeric antigen receptors (CARs)
[57], iPSC-derived autologous CAR-T-cells represent an interesting alternative to current pro-
tocols, as recently shown [19]. Finally, autologous, CCR5 knockout iPSC lines could present a
source to provide HIV patients with HIV-resistant T-cells to reconstitute the adaptive immune
system [58]. However, before iPSC-based cell therapies can enter clinical practice, safety con-
cerns, especially with regard to the generation of iPSC-derived teratoma, have to be addressed
and full functionality of iPSC-derived cells proven.
In conclusion, our study describes an iPSC-based disease model for RS-SCID. Our in vitro
protocol allowed us to differentiate iPSCs to T-cells and to analyze the influence of NHEJ defi-
ciency on V(D)J recombination. Moreover, it emphasizes the significance of designer nucleases
as a tool in generating isogenic disease models and their future role in producing iPSC-based,
patient-specific, genetically corrected autologous transplants for various applications in
the clinic.
Materials and Methods
Cells and cell culture
NIH.3T3 and HEK293T cells were cultured in DMEM (Biochrom) supplemented with 10%
FCS (PAA), penicillin/streptomycin (P/S; PAA), L-glutamine (Biochrom) and sodium
pyruvate (PAA). OP9 and OP9-DL1 cells (obtained from Juan Carlos Zúñiga-Pflücker)
were expanded in OP9 medium [alpha-MEM (Gibco), 20% OP9-tested FCS (PAA), P/S and
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L-glutamine]. Primary mouse ear fibroblasts were cultured in MEF medium [DMEM low glu-
cose (PAA) with 15% FCS, L-glutamine, nonessential amino acids (NEAA; Gibco), P/S,
100 μM of ß-mercaptoethanol (Sigma-Aldrich), sodium pyruvate and 50 μg/μl phospho-ascor-
bic acid (P-VitC, Sigma-Aldrich)]. ES.CCE cells were cultivated in ES medium [Knockout-
DMEM (Gibco) with 15% ES-tested FCS (PAA), P/S, L-glutamine, NEAA, 150 mMmonothio-
glycerol (MTG, Sigma-Aldrich) and ESGRO mouse LiF (Millipore)]. iPSCs were cultivated in
iPS medium [Knockout-DMEM supplemented with 15% ES-tested FCS, NEAA, P/S, L-Gluta-
mine, 100 μM of ß-mercaptoethanol and ESGRO mouse LiF, 50 μg/μl of P-VitC, 4 μM of
SB431542, 1 μM of PD0325901 and 3 μM of CHIR99021 (all Axon Medchem, together termed
3i) and passaged with Accutase (Gibco). ES.CCE cells and iPSCs were cultivated either on irra-
diated C3H or CF-1 MEF feeders on gelatin-coated plates or feeder-free in vented flasks (Sar-
stedt). Lineage negative cells (HSC) were isolated by flushing the tibiae and femurs of C57BL/
6N mice (Charles River) and purified by magnetic cell sorting (MACS) with the Lineage Cell
Depletion Kit (MACS Miltenyi) according to the manufacturer’s protocol. Cells were stained
with Trypan Blue (Sigma-Aldrich) and counted at 100x microscope magnification prior to in
vitro T-cell differentiation. Cell clones were generated either by limiting dilution (fibroblasts)
or colony picking (iPSCs). All but HEK293T cells were cultivated under hypoxic conditions
(7% CO2 / 5% O2).
Plasmids
Prkdc-specific zinc-finger arrays (S1 Fig) were generated with the OPEN protocol [32]. To gen-
erate ZFNs, the zinc-finger arrays were codon-optimized (GeneArt) and cloned into pRK5 vec-
tors, with and without NLS [59], containing the cleavage domains of wild-type FokI or the
obligate heterodimeric FokI variant KV/EA [55] and the LRGS linker [54]. The target plasmid
pCMV.LacZsPK@GFP was generated by replacing the “31” target site of pCMV.LacZs31@GFP
[59] by the ZFN target site aGTTTGCGCCtaactGAAGGTGACa (capital letters indicate target
site for ZFN). The donor plasmid pJet.SAE8586Neo (Fig 1A) consists of (i) a splice acceptor
(SA) [60]; (ii) a cDNA consisting of prkdc exons 85 and 86, which was PCR amplified from
pMEPK7 (kindly provided by Masumi Abe) with primers PRK-F/PRK-R (S2 Table); (iii) an
SV40 polyadenylation signal (pA); (iv) a NeoR cassette comprise the aminoglycoside phospho-
transferase coding sequence flanked by the HSV thymidine kinase promoter and an SV40 pA
(kindly provided by Stefan Weger); (v) left and right homology arms, which were PCR ampli-
fied from Fib.S gDNA.
Characterization of ZFN
For expression analysis, ZFNs were expressed in HEK293T for immunoblotting as previously
described [59]. The in vitro cleavage assay was basically performed as defined before [61].
Briefly, a target DNA was amplified by PCR from Fib.S gDNA using primers IV-F/IV-R (S2
Table). ZFNs were in vitro transcribed/translated with the TNT SP6 Coupled Reticulocytes Ly-
sate System (Promega), 150 ng of target DNA was mixed with the reticulocyte lysates, incubat-
ed for 1.5 h at 37°C, and analyzed on a 1.5% agarose gel. The plasmid-based gene targeting
assay was conducted as described before [59]. Flow cytometry to determine the percentage of
EGFP and REX positive cells was performed on FACSCalibur with CellQuestPro software (BD
Biosciences).
Gene targeting in RS-SCID cells
For targeted integration into Fib.S fibroblasts, 1x105 cells were transfected 24 h after seeding
with Lipofectamine 2000 (Life Technologies). 1.6 μg of endotoxin-free DNA was mixed with
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4.8 μl of transfection reagent in 200 μl OptiMEM (Gibco). The ZFN expression plasmids were
co-transfected with the donor pJet.SAE8586Neo at different ratios and filled up with pUC118
to 1.6 μg. Selection with 500 μg/ml of G418 (Sigma-Aldrich) was applied 5 days after transfec-
tion for 7 days. iPSCs were grown feeder-free before and after transfection. 3x106 cells were
nucleofected with 10 μg of pJET.SAE8586Neo and 5 μg of each ZFN expression plasmid using
the Mouse ES Cell Nucleofector Kit (LONZA) and Nucleofector II with program A-030. After
5 days of recovery, G418 selection was applied for 7 days at a concentration of 400 μg/ml. After
1 week, iPSC clones were isolated and cultivated on feeders.
Genotyping by PCR or Southern blotting
Genomic DNA was extracted with the QIAamp DNA Blood Mini Kit (QIAGEN). G418 select-
ed fibroblast and iPSC clones were analyzed for legitimate targeted integration by inside-out
PCR using Phire Hot Start II DNA polymerase kit (Thermo Scientific). RNA was isolated with
TRIzol (Life Technologies), and all RT-PCR reactions performed with the QuantiTect Reverse
Transcription Kit (QIAGEN). All used primers are listed in S2 Table. For Southern blot analy-
sis [62], genomic DNA was digested with EcoRV or BamHI, separated on a 0.8% agarose gel
and transferred to Biodyne B nylon membrane (PALL Life Sciences). DNA was hybridized
with a 32P-labeled fragment of PRE (for detection of the reprogramming vector) or NeoR (for
detection of donor copies) using the DecaLabel DNA Labeling Kit (Fermentas). Labeled Hin-
dIII digested Lambda DNA was used as a marker.
Functional tests to assay DNA-PK activity
To measure DNA-PK dependent RPA2 phosphorylation, 8x105 fibroblasts were treated with
1 μM of camptothecin (Sigma-Aldrich) for 1 h. Cells were harvested in RIPA buffer supple-
mented with Complete Protease Inhibitor and PhosSTOP phosphatase inhibitor cocktails
(both Roche). Western blot was basically performed as described before [63,64]. RPA2 and ß-
actin were detected with rat anti-RPA32 (1:1000, 4E4, Cell Signaling) and rabbit anti-ß-actin
(1:1000, Cell Signaling), respectively, and visualized with HRP-conjugated anti-rat and anti-
rabbit antibodies (1:20,000, Dianova) and West Pico Chemiluminescence substrate (Thermo
Scientific). For the colony survival assay, 1x105 fibroblasts were treated 1 day after seeding with
the indicated amounts of bleomycin (Sigma-Aldrich) for 2 h. Cells were washed with PBS, tryp-
sinized and 5,000 cells seeded into a 10-cm plate (N = 3). After 4 days the plates were stained
with 0.5% (w/MeOH) crystal violet (Sigma-Aldrich) and colonies counted.
Generation, excision and characterization of iPSC
Murine adult fibroblasts were extracted from ears of 6-week old NOD/ShiLtJ and NOD.
CB17-Prkdc scid/J male mice as described before [62]. Fibroblast from 12-week old NOD.
CB17-Prkdc scid/J mouse gave rise to spontaneously transformed Fib.S. The “4-in-1” repro-
gramming vector pRRL.PPT.SF.mOKSMco.idTom.PRE, co-expressing the transcription fac-
tors Oct4, Klf4, Sox2 and c-Myc with the fluorescent marker tdTomato, has been previously
described [35]. To generate versions that allow for Flp recombinas-mediated excision (pRRL.
PPT.SF.mOKSMco.idTom.PRE.FRT), FRT sites were introduced into the promoter-deprived
U3 region. Virus production has been described elsewhere [65]. The reprogramming was
conducted as described before [35]. Briefly, NOD.CB17-Prkdc scid/J or NOD/ShiLtJ-derived
fibroblasts were seeded in MEF medium on gelatin-coated 6-well-plates at 8x104/well for trans-
duction. After 2 days, cells were transduced with an MOI of 5 and incubated for 8 h, following
2 times washing with PBS. MEF medium with 2 mM VPA (Sigma Aldrich) was added. After 4
days medium was changed to iPS medium with VPA, and after 7 days 3i was added. After 14
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days, emerging iPSC colonies were isolated and expanded for characterization. A total of 12
iPSC clones derived from NOD.CB17-Prkdc scid/J (iPS.S) were initially characterized by as-
sessing expression of SSEA-1 by flow cytometry and staining of alkaline phosphatase (Milli-
pore) followed by documentation with the Olympus IX71 system. Determination of the vector
copy number (VCN), teratoma formation, Flp recombinase-mediated excision, fluorescence in
situ hybridization (FISH) and pluripotency factors RT-PCR analysis have been described previ-
ously [35,62,66]. Clone iPS.S6 was used for gene targeting and three out of 41 corrected clones
(iPS.T8, iPS.T25, iPS.T44) were characterized in detail. The parental uncorrected clone iPS.S6
was included as a negative control, a wild-type NOD/ShiLtJ derived clone (iPS.WT) as a
positive control.
In vitro T-cell differentiation
The protocol was adapted from previously published work [48,49]. For embryoid body (EB)
formation, iPSCs were split with Collagenase IV (Gibco) and 5x104 cells were cultured in sus-
pension plates in 2 ml of EB medium [IMDM (Biochrom AG) with 15% ES cult FCS (Stem
Cell Technologies), 5% PFHM II (Gibco), P/S, L-Glutamine, 50 μg/ml P-VitC, 150 mMMTG,
200 μg/ml human transferrin (Sigma-Aldrich)] in a normoxic incubator on a shaker at 60 rpm.
At day 2.5, 0.5 ml of EB medium plus cytokines rhBMP-4, activinA, rhVEGF165 and rhFGF-2
at 5 ng/ml final concentration each (all R&D Systems) was added. At day 8, EBs were har-
vested, washed with PBS and collected in Trypsin-EDTA, diluted 1:15 in Collagenase IV. After
30 min, 2.5 ml of cell dissociation buffer (Gibco) was added and cells transferred through a 70-
μmmesh. Hematopoietic progenitor cells (HPCs) were washed with PBS and analyzed for
CD41/cKit expression by flow cytometry prior to hematopoietic expansion. To this end, 106
EB-derived HPCs were cultivated for 3 days under hypoxic conditions in STFV medium
[IMDM, 10% OP9-tested FCS, P/S, L-glutamine, 10 ng/ml mSCF, 20 ng/ml mTPO, 100 ng/ml
rhFlt3-L (all Peprotech), and 40 ng/ml rhVEGF165 (R&D Systems) (final concentration
each)]. At day 3, cells were harvested through a 100-μmmesh and washed with PBS prior to in
vitro T-cell differentiation. To this end, up to 3x105 expanded HPCs or 0.5-1x105 HSCs were
added in T-cell differentiation medium [OP9 medium, supplemented with 1 ng/ml mIL-7
(Peprotech) and 5 ng/ml rhFlt3-L]. After 3 days, 2 ml medium was added and cultivation con-
tinued for up to 4 weeks. Every 7 days cells were harvested through a 100-μmmesh, washed
with PBS, transferred to a new OP9-DL1 cell layer, and analyzed for T-cell differentiation by
flow cytometry.
Analysis of T-cell phenotype and genotype
For flow cytometric analysis, cells were resuspended in FACS buffer [PBS supplemented with
2% FCS, 1 mM EDTA and 0.1% sodium azide (both Sigma-Aldrich)]. To stain for pluripotency
marker SSEA-1, iPSCs were rinsed with PBS and stained with biotinylated anti-SSEA-1 anti-
body (eBioscience) diluted in FACS buffer for 20 min at 4°C. After rinsing the secondary stain-
ing was performed with a streptavidin-APC antibody (eBioscience). Hematopoietic cells were
pretreated with Mouse BD Fc block (BD Biosciences) before antibody staining. Antibody stain-
ing was performed for 20 min at 4°C. EB-derived HPCs were stained with CD41-PE, cKit-
APC, or respective isotype controls (all eBioscience). iPSC-derived T-cells were stained with
CD44-PE and CD25-APC, or CD4-PE and CD8-APC. Viability staining with 7-AAD was per-
formed for 2 min during the last rinsing, before samples were measured on a FACSCalibur. Al-
ternatively, iPSC-derived T-cells were stained with CD45-APC-Cy7, CD4-PerCPR-Cy5.5,
CD8-PE-Cy7 (all BD Biosciences), CD44-PE, CD25-APC, TCRß-FITC (eBioscience) and
DAPI, before analysis on a FACSCanto II with FACSDiva (BD Biosciences). All samples were
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analyzed with FlowJo software (Tree Star). T-cell receptor diversity was analyzed by CDR3
spectratyping as previously described [67].
Statistics
All experiments were performed at least three times. Error bars represent standard deviation
(SD). Statistical significance was determined with a two-sided Student's t-test with
unequal variance.
Accession numbers
The National Center for Biotechnology Information (NCBI) Nucleotide database (http://www.
ncbi.nlm.nih.gov/nuccore) accession number for the ZFN target site in intron 84 of the prkdc
gene on mouse chromosome 16 is AB030754: 189732.
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S1 Table. Off-target site analysis.
(DOCX)
S2 Table. Sequences of primers used for characterization of gene targeted cells.
(DOCX)
S1 Text. Supplementary Methods.
(DOCX)
S1 Fig. ZFNs targeting prkdc locus. (A) Schematic view of ZFN binding site (ZFN BS) in
prkdc. The position and sequence of the ZFN BS in intron 84 is shown. F1, F2, F3 indicate tar-
get triplets for each binding half-sites. The spacer is highlighted in italics, mut indicates the
position of the SCID mutation. (B) Sequence of prkdc-specific ZF modules. Amino acid se-
quences of the ZF modules that recognize F1, F2, or F3 target triplets for the left and right tar-
get half-sites (5’ to 3’ orientation). Three ZFs for the left binding half-site (L1, L2, L3) and two
for the right target half-site (R1, R2) have been selected and tested for their ability to activate a
beta-galactosidase (ßgal) reporter [32]. (C) Expression analysis of ZFNs. ZFN-encoding plas-
mids were transfected in 293T cells and protein levels detected by immunoblotting using Odys-
sey IRDye antibodies. L1, L2, L3, ZFN left subunits 1, 2 or 3 with WT FokI domain; L1H, L2H,
L3H, ZFN left subunits 1, 2 or 3 with “EA” obligate heterodimeric FokI domain [55]; L2N,
ZFN left subunit L2 with “EA” obligate heterodimeric FokI domain without NLS signal; R1,
R2, ZFN right subunits 1 or 2 with WT FokI domain; R1H, R2H, ZFN right subunits 1 or 2
with “QK” obligate heterodimeric FokI domain [55]; R1N, R2N, ZFN right subunits 1 or 2
with “QK” obligate heterodimeric FokI domain without NLS signal. GFP served as transfection
and loading control. (D) In vitro cleavage assay. ZFN pair L2N and R1N was in vitro tran-
scribed/translated and mixed with a ZFN BS-containing PCR product. Cleavage reaction [61]
was analyzed on a 1.5% agarose gel. Size markers are indicated. (E) Plasmid-based gene correc-
tion assay. 293T cells were transfected with target plasmid, repair matrix and ZFN or SceI plas-
mids in order to induce episomal homology-directed repair [59]. Y axis shows the percentage
of relative gene correction frequency, which is calculated as GFP-positive cells (target plasmid
corrected) REX-positive cells (transfected cells). (+), positive control SceI; (-), negative control
SceIΔ; WT, L2 + R1 with homodimeric FokI domain; OH, L2 + R1 with obligate heterodimeric
FokI domain;-NLS, L2 + R1 with OH FokI domain without NLS signal.
(TIF)
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S2 Fig. Cellular characterization of iPSC clones. (A) Ssea-1 expression. Surface expression of
pluripotency marker Ssea-1 was measured by flow cytometry. Fib.S, NOD.SCID-derived ear fi-
broblasts; ES.CCE, murine ES cell line; iPS.S1, iPS.S6 and iPS.S12, NOD.SCID-derived iPSC
clones. (B) Alkaline phosphatase staining. NOD.SCID-derived iPSCs were stained using the
Alkaline Phosphatase Detection Kit and analyzed by microscopy. (C) Spectral karyotyping
(SKY). Multicolor fluorescent in situ hybridization (FISH) based karyotyping was used to as-
sess genome integrity. iPS.T8 and iPS.T44, gene targeted iPSC clones. (D) Teratoma Assay. He-
matoxylin/eosin-stained sections of teratoma isolated 8 weeks after injection of iPSCs into
NSG mice. Detection of ectodermal, endodermal and mesodermal tissues. iPS.T8 and iPS.T44,
gene targeted iPSC clones.
(TIF)
S3 Fig. Molecular characterization of iPSC clones. (A) Excision of the reprogramming cas-
sette. iPSCs have been treated with Flp recombinase to remove the lentiviral reprogramming cas-
sette. Excision was confirmed by detection of the viral PRE elements via Southern blot. Genomic
DNAwas digested with EcoRV or BamHI. Positions of restriction sites in reprogramming cassette
and the expected minimal band sizes are indicated on top. M, DNA size marker; S6 and S6X,
SCID iPSC clones; T25 and T25X, targeted iPSC clones; WT andWTX, wild-type iPSC clones; X
indicates clones with excised reprogramming cassette. (B) Random integration of donor. The
NeoR cassette, as an indicator of donor DNA, was detected by Southern blot to confirm targeted
integration in prkdc intron 84. Genomic DNA was digested with EcoRV orNdeI. Positions of re-
striction sites in the modified intron 84 and the expected band sizes are indicated on top. (C) De-
termination of vector copy number (VCN). Copy number of the lentiviral reprogramming vector
was assessed by quantitative PCR [62], and is indicated as PRE per endogenous Flk3 copy. Fib,
murine ear fibroblasts; iPS.1X and iPS.2X, iPSC clones with excised reprogramming cassette; iPS.
S1, iPS.S2, iPS.S3, iPS.S4, iPS.S6, iPS.S8, iPS.S9 and iPS.S12, NOD.SCID-derived iPSC clones.
(TIF)
S4 Fig. Control of in vitro differentiation. Samples were stained with CD41-PE, cKit-APC or
their corresponding isotype controls, and 7-AAD after dissociation of 8 d matured embryoid
bodies (EBs). All plots were pre-gated on FSC/SSC and 7-AAD-negativity. Red numbers indi-
cate percentage of cells in each quadrant. iPS.WT and iPS.WT X, wild-type iPSC clones; iPS.S6
and iPS.S6 X, SCID iPSC clones; iPS.T25, iPS.T25X and iPS.T44, targeted iPSC clones; X indi-
cates iPSC clones with excised reprogramming cassette.
(TIF)
S5 Fig. Analysis of T cell receptor diversity of in vitro generated T cells by spectratyping.
Quantitative PCR was performed on genomic DNA isolated from in vitro generated T cells. Ex-
emplarily shown are PCR analyses of the variable beta chains Vß1, Vß6, Vß8.1, Vß8.3, Vß10,
Vß12, Vß14 and Vß20. X axis indicates PCR fragment size in bp, Y axis shows quantity of PCR
amplicons. Thymus, control DNA of cells isolated from thymus; HSC, in vitro generated T
cells; iPS.WTX, wild-type iPSC clone; iPS.S6 and iPS.S6X, SCID iPSC clones; iPS.T25, iPS.
T25X and iPS.T44, targeted iPSC clones; X indicates clones with excised reprogramming cas-
sette.
(TIF)
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